Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …

Lipotoxicity is a fundamental pathophysiologic mechanism in diabetes and non-alcoholic
fatty liver disease and is now increasingly recognized in diabetic kidney disease (DKD) …

Aim To evaluate the impact of the sodium glucose co‐transporter 2 inhibitor canagliflozin on
intrahepatic triglyceride (IHTG) accumulation and its relationship to changes in body weight …

Background and rationale Activation of hepatic stellate cells (HSCs), the central event of
fibrosis, indicates the severe stage of non-alcoholic fatty liver disease (NAFLD). MicroRNAs …

The kidney plays a critical role in fluid homeostasis, glucose control, and drug excretion.
Loss of kidney function due to drug-induced nephrotoxicity affects over 20% of the adult …

Background and aims Scar tissue accumulation in organs is the underlying cause of many
fibrotic diseases. Due to the extensive array of organs affected, the long-term nature of …

Obesity is an important independent risk factor for cardiovascular diseases, remaining an
important health concern worldwide. Evidence shows that saturated fatty acid-induced …

Aims Non‐alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver
disease in Western countries and a common comorbidity with type 2 diabetes (T2D). It lacks …

Objectives The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal
outcomes has been revealed by large cardiovascular outcome trials among patients with …

Abstract Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …